When will the African classical swine fever vaccine be available?

On August 16, the Patent Bulletin for Invention on the website of the State Intellectual Property Office showed that Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences (Harbin Sub-center of Chinese Center for Animal Health and Epidemiology) published the patent for "Gene-deleted Attenuated African Swine Fever Virus and Its Application as Vaccine." The invention can be used as a safe and effective vaccine for preventing and controlling African swine fever epidemic situation in China, and has great social value. Industry insiders estimate that the successful development of African swine fever vaccine will take 8-10 years.

The research on African swine fever vaccine in China is led by Harbin Animal Research Institute. Earlier, the Scientific Research Progress Bulletin of the Chinese Academy of Agricultural Sciences reported that Harbin Animal Research Institute had successfully isolated the first African swine fever virus in China, created two candidate vaccine strains of African swine fever, and preliminarily completed the process research of pre-clinical pilot products. At present, the research and development of African swine fever vaccine of Harbin Animal Research Institute is in the laboratory research stage. Referring to the R & D process of biological products, the subsequent process includes neutral research, clinical research and new veterinary drug research.

African swine fever virus has been discovered as early as the early 20th century, but vaccine research lags behind more than 40 years. As things stand, gene-deletion vaccines can provide complete protection. Positive progress has been made in the research and development of African swine fever vaccine in China. The research institution has preliminarily completed the laboratory stage research of the candidate strain of gene deletion vaccine constructed independently, but the timetable cannot be determined. According to the African swine fever vaccine development roadmap issued by the European Union in 2017, it is estimated that the development of African swine fever vaccine will take 8-10 years. Tianfeng Securities believes that the potential market size reaches 15 billion yuan under the neutral condition of 600 million pigs and all market seedlings. In order to quickly control the epidemic situation and meet the market demand for vaccines, only qualified vaccine enterprises with production capacity are expected to obtain vaccine production license. It is expected that listed companies will become the first batch of non-epidemic vaccine manufacturers with high probability.